



21 Chang
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Room 1287
CASE NO. T-1092 - PATENT

Applicant : Raymond Baker, et al

Serial No. 07/827,187

Filed : January 28, 1992

For : IMIDAZOLE, TRIAZOLE AND
TETRAZOLE DERIVATIVES

Art Unit:

Examiner:

RECEIVED

MAY 13 1992

Commissioner of Patents and Trademarks
Washington, D. C. 20231

INFORMATION DISCLOSURE STATEMENT

GROUP 210

RECEIVED

MAY 16 1992

RECEIVED

GROUP 150

MAY 26 1992

Sir:

GROUP 210

In compliance with 37 CFR 1.99, Applicants wish to bring to the attention of the Examiner the art listed below and on the attached Form PTO-1449.

Their submission and listing on PTO-1449 is not to be construed as being complete or as an admission that any particular submitted reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

Applicants respectfully inform the Examiner that the foregoing references are discussed in the subject specification and request that said references be made of record.

92 JUL -8 PM 2:48
RECEIVED
GROUP 120



CAS 10.
PAGE:

T-1092Y
-2-

Foreign Patent Documents

EP-A-0313397 - Published

MAY 26 1992

RECEIVED

MAY 06 1992

Other Prior Art

GROUP 210

GROUP 150

1. A. Doenicke, et al, The Lancet, 1, 1309-11
(1988).
2. H. Bundgaard, Design of Prodrugs. ed.,
Elsevier, 1985.
3. J.F.W. McOmie, Protective Groups In Organic
Chemistry, ed. Plenum Press, 1973.
4. T.W. Greene, Protective Groups In Organic
Synthesis, John Wiley & Sons, 1981.
5. J. Neurosci., 7, 894 (1987).
6. Arch. Pharm., 342, 111 (1990).

Respectfully submitted,

By Manfred Polk
Manfred Polk
Reg. No. 27,102
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(908)594-4285

Date: April 27, 1992

MP:kah
encl.
2089s/2